<DOC>
	<DOCNO>NCT02747004</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy abemaciclib plus tamoxifen abemaciclib alone woman previously treat hormone receptor-positive ( HR+ ) , human epidermal growth factor receptor 2 negative ( HER2- ) , metastatic breast cancer .</brief_summary>
	<brief_title>A Study Abemaciclib ( LY2835219 ) Plus Tamoxifen Abemaciclib Alone Women With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Loperamide</mesh_term>
	<mesh_term>Antidiarrheals</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Have diagnosis HR+ , HER2 breast cancer . Relapsed progress follow endocrine therapy . Have receive prior treatment least 2 chemotherapy regimen , least 1 2 administer metastatic setting . Have presence measureable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) . Have performance status â‰¤1 Eastern Cooperative Oncology Group ( ECOG ) scale . Have discontinue previous therapy cancer ( include specifically , aromatase inhibitor , antiestrogens , chemotherapy , radiotherapy , immunotherapy ) least 21 day myelosuppressive agent 14 day nonmyelosuppressive agent prior receive study drug , recover acute effect therapy ( toxicity resolve either baseline least Grade 1 ) except residual alopecia peripheral neuropathy . Have adequate organ function . Have negative serum pregnancy test within 7 day prior first dose study treatment agree use highly effective precaution prevent pregnancy study 12 week follow last dose study treatment . Are able swallow oral medication . Have clinical evidence history central nervous system metastasis . Have receive treatment drug receive regulatory approval indication within 14 21 day prior randomization study drug nonmyelosuppressive myelosuppressive agent , respectively . Have major surgery within 14 day prior randomization study drug allow postoperative healing surgical wound site ( ) . Have personal history follow condition : syncope either unexplained cardiovascular etiology , ventricular tachycardia , ventricular fibrillation , sudden cardiac arrest . Have active bacterial fungal infection ( , require intravenous antibiotic time initiate study treatment ) and/or detectable viral infection . Have receive treatment prior cyclindependent kinase ( CDK4 ) CDK 6 inhibitor . Have preexist chronic condition result persistent diarrhea . Have history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix breast ) , unless complete remission therapy minimum 3 year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>